AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04731467
Drug: CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Expansion cohort of CM24 in combination with nivolumab, nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
Trial: NCT04731467
Drug: CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Expansion cohort of CM24 in combination with nivolumab and Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
Trial: NCT06704893
Drug: Normal saline injection group
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive intra-articular knee injections under ultrasound guidance with 3 ml of sterile normal saline.
Trial: NCT04731467
Drug: Nivolumab, Nab paclitaxel and Gemcitabine - Expansion
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Expansion cohort of nivolumab in combination with nab-paclitaxel and gemcitabine in adult patients with advanced metastatic pancreatic cancer
Trial: NCT04731467
Drug: Nivolumab and Nal-IRI/5-FU/LV - Expansion
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Expansion cohort of nivolumab in combination with Nal-IRI/5-FU/LV in adult patients with advanced metastatic pancreatic cancer
Trial: NCT06275919
Drug: Regorafenib 40 MG Oral Tablet
RxNorm normalized name: regorafenib 40 MG Oral Tablet
DrugBank: Regorafenib (DB08896)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity
Trial: NCT04856293
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single 250 mg crizotinib dose of the FC formulation
Trial: NCT04856293
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation administered by sprinkling the contents into a dry glass vial
Trial: NCT04856293
Drug: Crizotinib
RxNorm normalized name: Crizotinib
DrugBank: Crizotinib (DB08865)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single 250 mg crizotinib dose of the single 250 mg crizotinib dose of the encapsulated microsphere (eMS) formulation (administered as intact capsules) . The intact capsules will be swallowed whole.
Trial: NCT06706713
Drug: BEBT-109 Capsule
RxNorm normalized name: bebtelovimab
DrugBank: Bebtelovimab (DB16755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take orally before breakfast and dinner each day, with a minimum interval of 9 hours between doses, 120mg each time, twice a day,and 28 days as a treatment cycle.
Trial: NCT06704828
Drug: SHR-4602
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-4602
Trial: NCT06244082
Drug: AOC 1044
RxNorm normalized name: AOC 1001
DrugBank: AOC 1001 (DB18620)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AOC 1044 will be administered via intravenous (IV) infusion
Trial: NCT03775174
Drug: Mepsevii
RxNorm normalized name: Mepsevii
DrugBank: Vestronidase alfa (DB12366)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04188665
Drug: MASL
RxNorm normalized name: MENTHOL 1.25 g in 100 g / CAMPHOR (NATURAL) 5 g in 100 g / METHYL SALICYLATE 10 g in 100 g TOPICAL OINTMENT [Manteca Maslac]
DrugBank: Camphor (DB01744)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients treated with MASL lozenge
Trial: NCT06706414
Drug: Denosumab (Prolia)
RxNorm normalized name: Denosumab
DrugBank: Denosumab (DB06643)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Subcutaneous injection with 60 mg Denosumab once
Trial: NCT04840199
Drug: Letermovir Oral Tablet
RxNorm normalized name: letermovir Oral Tablet
DrugBank: Letermovir (DB12070)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 480 mg administered orally once daily with or without food
Trial: NCT06103266
Drug: Rivaroxaban
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Once daily rivaroxaban 20 mg or 15 mg with reduced kidney function (eGFR 15 - 49 mmol/L) for 6 months in case of percutaneous coronary intervention for stable coronary artery disease or 12 months in case of percutaneous coronary intervention for acute coronary syndrome without concurrent antiplatelet therapy
Trial: NCT04990349
Drug: Oxygen gas
RxNorm normalized name: oxygen Gas for Inhalation
DrugBank: Oxygen (DB09140)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Targeted PO2 postoxygenator is obtained by modulating ECMO Membrane oxygen fraction.
Trial: NCT04159597
Drug: Upadacitinib
RxNorm normalized name: Upadacitinib
DrugBank: Upadacitinib (DB15091)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Upadacitinib will be administered as oral solution.
Trial: NCT05556616
Drug: Modakafusp alfa
RxNorm normalized name: Modakafusp alfa
DrugBank: Modakafusp alfa (DB16399)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modakafusp alfa intravenous infusion.
Trial: NCT05556616
Drug: Lenalidomide
RxNorm normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lenalidomide capsules orally.
Trial: NCT05556616
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bortezomib injection subcutaneously.
Trial: NCT05556616
Drug: Carfilzomib
RxNorm normalized name: Carfilzomib
DrugBank: Carfilzomib (DB08889)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Carfilzomib intravenous infusion.
Trial: NCT05556616
Drug: Daratumumab
RxNorm normalized name: Daratumumab
DrugBank: Daratumumab (DB09331)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Daratumumab injection subcutaneously.
Trial: NCT05556616
Drug: Pomalidomide
RxNorm normalized name: Pomalidomide
DrugBank: Pomalidomide (DB08910)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pomalidomide capsules orally.
Trial: NCT06342713
Drug: BGB-45035
RxNorm normalized name: BGB-DXP593
DrugBank: BGB-DXP593 (DB16357)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT04715867
Drug: Rabix-VC
RxNorm normalized name: phenylephrine hydrochloride / promethazine hydrochloride Oral Solution [Phenergan VC]
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabix-VC will be locally manufactured by Incepta Vaccine Ltd
Trial: NCT04989699
Drug: Aflibercept/Sham
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aflibercept administered every 8 weeks
Trial: NCT06705322
Drug: Cnidium Monnieri Detoxification Formula
RxNorm normalized name: Cnidium monnieri fruit oil
DrugBank: Fica (DB03384)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug composition of Cnidium Monnieri Detoxification Formula: snake seed 9g, Tuckaia 30g, Matrine 9g, snake berry 30g, white Ying 30g. Based on the Cnidium Monnieri Detoxification Formula, the other symptoms were treated with syndrome differentiation and flavor. The traditional Chinese medicine decoction is provided by the Pharmacy of Yueyang Hospital of Integrated Traditional Chinese and Western Medicine Affiliated to Shanghai University of Traditional Chinese Medicine, with 1 dose per day, decocted into 300ml by a medicine decocter, packed in 2 vacuum bags, taken orally after meals, twice a day, one bag each time. Do not stop taking decoction during menstruation. 1 month is a course of treatment, at least 3 courses of treatment, no more than 6 courses of treatment.~Baseline HPV clearance, improvement in clinical symptoms and quality of life, and drug safety were assessed at 3 months, 6 months, and 12 months after initiation of treatment.
Trial: NCT06704581
Drug: 10 mg BGM0504 injection administered subcutaneously (SC) once a week
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10mg BGM0504 injection administered subcutaneously (SC) once a week.
Trial: NCT06056596
Drug: Lamivudine 300 MG
RxNorm normalized name: lamivudine 300 MG
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Drug to be taken once daily for three days (two days prior to surgery and on the morning of surgery)
Trial: NCT06472583
Drug: Keytruda
RxNorm normalized name: Keytruda
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Preoperative immunotherapy (200 mg, infusion every 21 days, 4 administrations planned)
Trial: NCT05594758
Drug: Olverembatinib
RxNorm normalized name: Olverembatinib
DrugBank: HQP1351 (DB16185)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Olverembatinib
Trial: NCT06279351
Drug: Thalidomide+cetuximab+FOLFOX/FOLFIRI
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Thalidomide+cetuximab+FOLFOX/FOLFIRI
Trial: NCT05687851
Drug: Cadonilimab（AK104）
DrugBank: Cadonilimab (DB16680)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: q3w iv
Trial: NCT04874025
Drug: Ibrance
RxNorm normalized name: Ibrance
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Observational study of Ibrance 75 mg, 100 mg and 125 mg.
Trial: NCT05954962
Drug: Progesterone 200 MG
RxNorm normalized name: progesterone 200 MG
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The patients in the study group will administer oral natural micronized progesterone capsules from day 1 of ovarian stimulation instead of antagonist (ganirelix) subcutaneaous injections from day 5-6 of stimulation.
Trial: NCT05954962
Drug: Ganirelix Acetate
RxNorm normalized name: Ganirelix Acetate
DrugBank: Ganirelix (DB06785)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patients in the control group will administer subcutaneaous injections of ganirelix from day 5-6 of stimulation as per currently used protocol.
Trial: NCT04984837
Drug: Lacutamab
RxNorm normalized name: Lacutamab
DrugBank: Lacutamab (DB15322)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 750 mg/IV
Trial: NCT04984837
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1000 mg/m²
Trial: NCT04984837
Drug: Oxaliplatine
RxNorm normalized name: oxaliplatine
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 mg/m²
Trial: NCT06507306
Drug: osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral osimertinib
Trial: NCT06290102
Drug: Fp MDPI
RxNorm normalized name: Coagulation Factor IX (Recombinant), Albumin Fusion Protein (rIX-FP)
DrugBank: Albutrepenonacog alfa (DB13884)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form: Dry powder~Route of administration: Oral inhalation
Trial: NCT06036745
Drug: Pembrolizumab + SOX
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pembrolizumab 200mg, ivdrip, q3w; Oxaliplatin 135mg/m2, ivdrip，q3w; Trastuzumab 40 mg/m2，po bid，d1\~d14，q21d. Each cycle consists of three weeks, totaling eight cycles
Trial: NCT04884009
Drug: SHR-1701； Famitinib
DrugBank: Famitinib (DB11741)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1701+ Famitinib
Trial: NCT04884009
Drug: SHR-1701
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1701
Trial: NCT06001047
Drug: Group B
RxNorm normalized name: Blood group B IgM
DrugBank: Neisseria meningitidis serogroup B recombinant LP2086 A05 protein variant antigen (DB10284)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The original text is related to a medication called Pitavastatin Calcium Tablets, commonly known as Minshilang in Chinese, produced by Weicai (China) Pharmaceutical Co., Ltd. The dosage is 12mg, three times a day (Tid) for four consecutive weeks. Compliance monitoring is conducted by counting the remaining tablets in the medication packaging box brought by patients during the 4-week follow-up period. Concurrent use of other medications that may affect the observation results, such as anti-anxiety drugs, vestibular suppressants, and anti-dizziness Chinese patent medicines, is considered a violation of the protocol.
Trial: NCT06390059
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab is a humanized IgG1 monoclonal antibody which targets human PD-L1and inhibits its interaction with its receptors, PD-1 and B7.1 (CD80). Both of these interactions are reported to provide inhibitory signals to T cells. Atezolizumab is administered as an intravenous solution.~Atezolizumab may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Trial: NCT06390059
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine is a standard of care chemotherapy drug administered as an intravenous infusion.~Gemcitabine may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Trial: NCT06390059
Drug: nab-paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nab-paclitaxel is a standard of care chemotherapy drug administered as an intravenous infusion.~Nab-paclitaxel may continue until disease progression according to RECIST v1.1 or loss of clinical benefit.
Trial: NCT05004610
Drug: Sodium Lactate Solution
RxNorm normalized name: sodium lactate Injectable Solution
DrugBank: Lactic acid (DB04398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: continuous intravenous infusion of molar sodium lactate
Trial: NCT02119728
Drug: HPPH
RxNorm normalized name: HPPH
DrugBank: 2-(1-Hexyloxyethyl)-2-devinyl pyropheophorbide-a (DB15243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Undergo photodynamic therapy with HPPH
Trial: NCT06134479
Drug: 150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 2 or 3 of the menstrual cycle, a first subcutaneous (SC) injection of corifollitropin alfa (CFA) (Elonva®) 150μg will be administered (stimulation day 1) and a second SC injection of corifollitropin alfa (Elonva®) 100 μg will be administrated on SD 5. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
Trial: NCT06134479
Drug: 150μg CFA (Elonva®) at SD 1 following by rFSH (Puregon®) 200IU daily from SD 8 until the day of the trigger
RxNorm normalized name: Alphanine SD
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: On Day 2 or 3 of the menstrual cycle, a single subcutaneous (SC) injection of corifollitropin alfa (Elonva®) 150μg will be administered (SD 1) and from Day 8 of stimulation a daily SC dose of rFSH (Puregon®) 200IU/day up to the day of Triptorelin (Decapeptyl®) 0.2 mg administration. Endogenous LH suppression will be accomplished by daily 75μg/day of Desogestrel (Cerazet®) per os, at bedtime, starting on stimulation day 1 and continuing up to the day before of trigger. As soon as 3 follicles ≥ 18 mm are observed by ultrasound, 0.2 mg Triptorelin (Decapeptyl®) will be administered the same day to induce final oocyte maturation. About 34-36 hours thereafter oocyte pick-up will be performed.
Trial: NCT06136741
Drug: Rezpegaldesleukin
RxNorm normalized name: Rezpegaldesleukin
DrugBank: Rezpegaldesleukin (DB18992)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: subcutaneous
Trial: NCT05518903
Drug: Gallium Ga 68 FAPi-46
RxNorm normalized name: Gallium Ga 68 FAPi-46
DrugBank: FAPi-46 GA-68 (DB18827)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04947553
Drug: AXS-05 (dextromethorphan-bupropion)
RxNorm normalized name: AX
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AXS-05 tablets, taken twice daily
Trial: NCT05944809
Drug: rhTPO
RxNorm normalized name: rhTPO
DrugBank: Recombinant Human Thrombopoietin (DB16364)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment options:~Radiotherapy: 95% planning target volume （planning target volume，PTV） ≥45Gy(without simultaneous boost).~Concurrent chemotherapy:~Weekly regimen: paclitaxel 50mg/m2 d1, nedaplatin/cisplatin 25 mg/m2d1, a total of 5 cycles.~Three weeks regimen: paclitaxel 135-175mg/m2 d1, nedaplatin/cisplatin 80mg/m2, a total of 2 cycles.~The active bone marrow was determined by magnetic resonance（magnetic resonance，MR）, and the dose limits are: V5\<95%,V10\<85%,V20\<60%，V30\<40%；95%PTV\>45Gy.~rhTPO，15000U ih. qw(during the radiotherapy course)
Trial: NCT04880278
Drug: Nabilone
RxNorm normalized name: Nabilone
DrugBank: Nabilone (DB00486)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Half of the participants (30 individuals) will receive nabilone 1mg. Nabilone will be placed in opaque capsules with dextrose filler and administered by mouth only once (around 120 minutes prior to fMRI scanning).
Trial: NCT05720117
Drug: PYX-201
RxNorm normalized name: PYX-201
DrugBank: PYX-201 (DB18382)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion
Trial: NCT05650411
Drug: Conventional DAPT
RxNorm normalized name: DAPT
DrugBank: Diaminopropanol tetraacetic acid (DB12362)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 to 12 months of DAPT combining aspirin (≥75 mg od) and a P2Y12 inhibitor (clopidogrel 75 mg od, ticagrelor 90 mg bd, prasugrel 5 or 10 mg od at the discretion of the investigator) followed by aspirin SAPT.
Trial: NCT05222516
Drug: Broncho-Vaxom
RxNorm normalized name: Broncho-Vaxom
DrugBank: OM85 (DB16533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily administration of Broncho-Vaxom 3.5mg capsules
Trial: NCT05556512
Drug: Tirzepatide
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT00000799
Drug: Cidofovir
RxNorm normalized name: Cidofovir
DrugBank: Cidofovir (DB00369)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00000799
Drug: Probenecid
RxNorm normalized name: Probenecid
DrugBank: Probenecid (DB01032)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06199791
Drug: Lamotrigine 100 MG
RxNorm normalized name: lamotrigine 100 MG
DrugBank: Lamotrigine (DB00555)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: tablets
Trial: NCT06241118
Drug: Amlitelimab
RxNorm normalized name: Amlitelimab
DrugBank: Amlitelimab (DB18835)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Injection solution Route of administration: Subcutaneous
Trial: NCT06241118
Drug: Topical tacrolimus or pimecrolimus
RxNorm normalized name: pimecrolimus Topical Cream
DrugBank: Pimecrolimus (DB00337)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: Various Topical formulation Route of administration: Topical
Trial: NCT05032157
Drug: LOU064 (open-label)
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LOU064 (open-label) active treatment
Trial: NCT05193227
Drug: ST-01
RxNorm normalized name: CE-VST-01-JC
DrugBank: CE-VST01-JC (DB17190)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of up to 8 mL ST-01 (70 mg/mL lidocaine)
Trial: NCT05193227
Drug: Control (Lidocaine Hydrochloride Injection USP Xylocaine® or Bupivacaine Hydrochloride Injection USP Marcaine®)
RxNorm normalized name: Afeditab CR
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration of up to 3 mg/kg bupivacaine hydrochloride injection (0.25%) or up to 4.5mg/kg lidocaine hydrochloride injection (0.5-1%)
Trial: NCT06782048
Drug: Pyrvinium
RxNorm normalized name: pyrvinium
DrugBank: Pyrvinium (DB06816)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive pyrvinium (2 mg/kg/day) by mouth once each day for a total of 14 days.
Trial: NCT06218290
Drug: Oxylanthanum Carbonate
RxNorm normalized name: Lanthanum Carbonate
DrugBank: Lanthanum carbonate (DB06792)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Phosphate Binder to Reduce Hyperphosphatemia
Trial: NCT05332340
Drug: BZ371A
RxNorm normalized name: BZ371A
DrugBank: BZ371A (DB18101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose topical administration of 1.5 mL with a concentration of 5 mg/mL of BZ371A.
Trial: NCT05138575
Drug: Empagliflozin + Potassium Chloride
RxNorm normalized name: Empagliflozin
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle.~KCl is an active control.
Trial: NCT05138575
Drug: Empagliflozin + Potassium Nitrate
RxNorm normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Empagliflozin + KNO3 is the active intervention that may improve mitochondrial function and energy fuel metabolism in skeletal muscle, as well as increase skeletal muscle perfusion during exercise.
Trial: NCT05138575
Drug: Potassium Chloride + Placebo for Empagliflozin
RxNorm normalized name: potassium chloride Powder for Oral Solution
DrugBank: Potassium chloride (DB00761)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active control.
Trial: NCT04670081
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25 mg, p.o.
Trial: NCT04670081
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg, p.o.
Trial: NCT06738368
Drug: Asparaginase Erwinia chrysanthemi
RxNorm normalized name: Asparaginase Erwinia chrysanthemi
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IM
Trial: NCT06738368
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given CIV